Capstone Financial Advisors Inc. Lowers Holdings in Abbott Laboratories $ABT

Capstone Financial Advisors Inc. lowered its holdings in Abbott Laboratories (NYSE:ABT) by 11.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,312 shares of the healthcare product maker’s stock after selling 441 shares during the quarter. Capstone Financial Advisors Inc.’s holdings in Abbott Laboratories were worth $450,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Brighton Jones LLC lifted its position in Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares during the last quarter. SeaBridge Investment Advisors LLC purchased a new stake in shares of Abbott Laboratories in the 1st quarter valued at approximately $215,000. Summit X LLC acquired a new position in shares of Abbott Laboratories in the 1st quarter worth approximately $240,000. Napatree Capital LLC increased its holdings in Abbott Laboratories by 8.6% in the 1st quarter. Napatree Capital LLC now owns 2,023 shares of the healthcare product maker’s stock valued at $268,000 after purchasing an additional 160 shares during the last quarter. Finally, Ascent Wealth Partners LLC raised its position in Abbott Laboratories by 4.5% in the first quarter. Ascent Wealth Partners LLC now owns 98,472 shares of the healthcare product maker’s stock valued at $13,062,000 after purchasing an additional 4,285 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Barclays raised their price target on Abbott Laboratories from $159.00 to $162.00 and gave the stock an “overweight” rating in a research report on Friday, October 17th. Royal Bank Of Canada restated an “outperform” rating and set a $147.00 target price on shares of Abbott Laboratories in a report on Thursday, October 16th. Raymond James Financial boosted their price target on shares of Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a research note on Thursday, October 16th. Sanford C. Bernstein increased their price target on shares of Abbott Laboratories from $145.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. Finally, Benchmark initiated coverage on shares of Abbott Laboratories in a report on Friday, October 10th. They issued a “buy” rating and a $145.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $147.00.

Abbott Laboratories Stock Performance

Shares of ABT opened at $129.16 on Friday. The stock has a 50-day simple moving average of $130.42 and a 200-day simple moving average of $131.34. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23. The stock has a market capitalization of $224.59 billion, a PE ratio of 16.19, a PEG ratio of 2.36 and a beta of 0.68.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The firm had revenue of $11.37 billion for the quarter, compared to analysts’ expectations of $11.40 billion. During the same quarter last year, the company earned $1.21 earnings per share. The firm’s revenue was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories’s payout ratio is presently 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.